{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-21-003222","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2021-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.317191+00:00","generated_at":"2026-06-29T23:47:44.804945+00:00","sec_items":["8.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"PharmaCyte Biotech reports preliminary FY2021 net loss of $3.6M, cash $2.2M","bullets":["Net loss for FY2021 was approx. $3.6M ($2.45 loss per share) vs. $3.8M ($4.23 loss per share) in FY2020.","Cash on hand as of April 30, 2021 was approx. $2.2M.","Results are preliminary and unaudited, subject to completion of financial closing procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-21-003222","json":"https://secwatch.observer/filing/0001683168-21-003222.json","markdown":"https://secwatch.observer/filing/0001683168-21-003222.md","text":"https://secwatch.observer/filing/0001683168-21-003222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316821003222/0001683168-21-003222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316821003222/pharma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T23:47:44.804945+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}